SOLIGENIX INC(NASDAQ:SNGX) stock Fundamental Analysis

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to SNGX. SNGX was compared to 572 industry peers in the Biotechnology industry. While SNGX seems to be doing ok healthwise, there are quite some concerns on its profitability. SNGX does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year SNGX has reported negative net income.

In the past year SNGX has reported a negative cash flow from operations.

SNGX had negative earnings in each of the past 5 years.

In the past 5 years SNGX always reported negative operating cash flow.

1.2 Ratios

With a Return On Assets value of -67.76%, SNGX is not doing good in the industry: 64.30% of the companies in the same industry are doing better.

SNGX has a Return On Equity (-119.61%) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
ROA	-67.76%
ROE	-119.61%
ROIC	N/A

ROA(3y)-68.67%

ROA(5y)-83.05%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

SNGX has a Gross Margin of 6.39%. This is in the better half of the industry: SNGX outperforms 73.53% of its industry peers.

In the last couple of years the Gross Margin of SNGX has remained more or less at the same level.

SNGX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	6.39%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-20.28%

GM growth 5Y-1.04%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

SNGX does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for SNGX has been reduced compared to 1 year ago.

The number of shares outstanding for SNGX has been reduced compared to 5 years ago.

The debt/assets ratio for SNGX has been reduced compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -31.84, we must say that SNGX is in the distress zone and has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -31.84, SNGX is doing worse than 91.47% of the companies in the same industry.

There is no outstanding debt for SNGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-31.84

ROIC/WACCN/A

WACC10.04%

2.3 Liquidity

SNGX has a Current Ratio of 2.28. This indicates that SNGX is financially healthy and has no problem in meeting its short term obligations.

SNGX has a Current ratio of 2.28. This is in the lower half of the industry: SNGX underperforms 74.07% of its industry peers.

A Quick Ratio of 2.28 indicates that SNGX has no problem at all paying its short term obligations.

SNGX has a worse Quick ratio (2.28) than 72.65% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.28
Quick Ratio	2.28

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 89.84% over the past year.

The Revenue for SNGX has decreased by -62.46% in the past year. This is quite bad

SNGX shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -30.67% yearly.

EPS 1Y (TTM)89.84%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%69.53%

Revenue 1Y (TTM)-62.46%

Revenue growth 3Y-29.15%

Revenue growth 5Y-30.67%

Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, SNGX will show a very strong growth in Earnings Per Share. The EPS will grow by 23.37% on average per year.

The Revenue is expected to grow by 4.11% on average over the next years.

EPS Next Y62.08%

EPS Next 2Y34.44%

EPS Next 3Y23.37%

EPS Next 5YN/A

Revenue Next Year-36.11%

Revenue Next 2Y6.23%

Revenue Next 3Y4.11%

Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SNGX. In the last year negative earnings were reported.

Also next year SNGX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

SNGX's earnings are expected to grow with 23.37% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y34.44%

EPS Next 3Y23.37%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

SNGX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

SOLIGENIX INC

NASDAQ:SNGX (2/21/2025, 8:00:02 PM)

After market: 2.3515 -0.08 (-3.23%)

2.43

-0.01 (-0.41%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-09 2024-11-09/dmh

Earnings (Next)03-13 2025-03-13/amc

Inst Owners1.35%

Inst Owner Change-53.77%

Ins Owners0.02%

Ins Owner Change0%

Market Cap6.10M

Analysts82.86

Price Target22.95 (844.44%)

Short Float %4.82%

Short Ratio0.44

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)28.74%

Min EPS beat(2)27.64%

Max EPS beat(2)29.84%

EPS beat(4)3

Avg EPS beat(4)12.24%

Min EPS beat(4)-15.64%

Max EPS beat(4)29.84%

EPS beat(8)6

Avg EPS beat(8)-9.56%

EPS beat(12)8

Avg EPS beat(12)-9.34%

EPS beat(16)11

Avg EPS beat(16)-5.17%

Revenue beat(2)0

Avg Revenue beat(2)-99.43%

Min Revenue beat(2)-100%

Max Revenue beat(2)-98.85%

Revenue beat(4)0

Avg Revenue beat(4)-61.72%

Min Revenue beat(4)-100%

Max Revenue beat(4)-5.39%

Revenue beat(8)3

Avg Revenue beat(8)-21%

Revenue beat(12)6

Avg Revenue beat(12)0.67%

Revenue beat(16)6

Avg Revenue beat(16)-13.3%

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)-375%

EPS NY rev (1m)0%

EPS NY rev (3m)3.75%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)0%

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	16.75
P/FCF	N/A
P/OCF	N/A
P/B	1.03
P/tB	1.03
EV/EBITDA	N/A

EPS(TTM)-8.65

EYN/A

EPS(NY)-2.99

Fwd EYN/A

FCF(TTM)-3.19

FCFYN/A

OCF(TTM)-3.19

OCFYN/A

SpS0.15

BVpS2.36

TBVpS2.36

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-67.76%
ROE	-119.61%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	6.39%
FCFM	N/A

ROA(3y)-68.67%

ROA(5y)-83.05%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-20.28%

GM growth 5Y-1.04%

F-Score3

Asset Turnover0.03

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.28
Quick Ratio	2.28
Altman-Z	-31.84

F-Score3

WACC10.04%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)89.84%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%69.53%

EPS Next Y62.08%

EPS Next 2Y34.44%

EPS Next 3Y23.37%

EPS Next 5YN/A

Revenue 1Y (TTM)-62.46%

Revenue growth 3Y-29.15%

Revenue growth 5Y-30.67%

Sales Q2Q%-100%

Revenue Next Year-36.11%

Revenue Next 2Y6.23%

Revenue Next 3Y4.11%

Revenue Next 5YN/A

EBIT growth 1Y13.86%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y33.93%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y33.82%

OCF growth 3YN/A

OCF growth 5YN/A

SOLIGENIX INC (SNGX) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens